The phase III SKYSCRAPER-01 did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
Initial results from the ANTLER phase I trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) demonstrated a 100% overall response rate and 80% complete response rate in cohort 1 (n=5 evaluable).
Cancer Research UK and the Stichting Oncode Institute, an independent research institute in the Netherlands, formed a strategic alliance focused on translating cancer research into benefits for patients.
FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.
NEXT Oncology – Madrid enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer with an anti-drug conjugate used in monotherapy or in combination with antiPDL1. NEXT Oncology expanded to Spain in late 2021.
C2i Genomics launched its C2inform minimal residual disease test across Europe after obtaining CE-IVD marking in the EU, UK, and Switzerland. The company also announced the completion of several clinical trials.
Genentech announced that the phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival.
Positive top-line data from the monotherapy arm of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrated that Rubraca (rucaparib) as maintenance treatment achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with placebo.
The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.
Charles Edward Geyer Jr. will join UPMC Hillman Cancer Center as co-director of its NCI National Clinical Trials Network efforts.
